{"url_path":"/sec/tara/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-055463-index.html","accession_number":"0001213900-26-055463","cik":"0001359931","ticker":"TARA","issuer_name":"Protara Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-055463-index.html","primary_entity_key":"0001359931","primary_entity_name":"Protara Therapeutics, Inc."},"word_count":80,"has_tables":true,"body_markdown":"**Item 1. Legal Proceedings**\n\n** **\n\nFrom time to time, we may\nbe subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We are not currently\na party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business.\nRegardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources\nand other factors."}